Invited Speaker

Four New Anticancer Drugs: Cardiovascular Hormones Treatment of Human Pancreatic, Breast and Small-cell Lung Cancers in Athymic Mice
David L. Vesely
USA

One gene in the heart synthesizes a 126 amino acid prohormone which contains four cardiac hormones, i.e., long acting natriuretic peptide, vessel dilator, kaliuretic peptide and atrial natriuretic peptide. These peptide hormones decrease up to 97% of human pancreatic, breast, colon, ovarian, kidney and prostate adenocarcinomas as well as glioblastomas of the brain, small-cell and squamous cell lung carcinoma cells in vitro. When infused subcutaneously for 28 days with weekly fresh hormones at 3 nM min-1 kg-1 body weight in athymic mice, they eliminate up to 80% of the human pancreatic adenocarcinomas, 2/3rds of human breast adenocarcinomas, and up to 86% of human small-cell lung cancers with treated mice living a normal lifespan. These cancers never reoccur in the primary site. Their mechanisms(s) of action in cancer cells includes a 95% inhibition of Ras, 96% with treated mice, ERK 1/2 and 98% inhibition of mitogen-activated protein kinases MEK 1/2. These inhibitions are mediated by the intracellular mediator cyclic GMP. These cardiac hormones inhibit the proliferation of human pancreatic cancer cells up to 73% at their 0.01 μM concentration and 81% at their 0.1 μM concentrations while sparing normal human lung, kidney, prostate and endothelial cells from a similar antiproliferative effect.